MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy.
MAGE- A10
NY-ESO-1
immunohistochemistry
ovarian cancer
platinum sensitivity
prognosis
response to platinum-based chemotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Sep 2023
23 Sep 2023
Historique:
received:
23
08
2023
revised:
17
09
2023
accepted:
21
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Ovarian cancer has a dismal prognosis. Standard treatment following surgery relies on platinum-based chemotherapy. However, sizeable percentages of patients are unresponsive. Identification of markers predicting the response to chemotherapy might help select eligible patients and spare non-responding patients from treatment-associated toxicity. Cancer/testis antigens (CTAs) are expressed by healthy germ cells and malignant cells of diverse histological origin. This expression profile identifies them as attractive targets for cancer immunotherapies. We analyzed the correlations between expression of MAGE-A10 and New York esophageal-1 cancer (NY-ESO-1) CTAs at the protein level and the effectiveness of platinum-based chemotherapy in patients with advanced-stage high-grade serous ovarian carcinoma (HGSOC). MAGE-A10 and NY-ESO-1 protein expression was analyzed by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded samples from 93 patients with advanced-stage HGSOC treated at our institutions between January 1996 and December 2013. The correlation between the expression of these markers and response to platinum-based chemotherapy, evaluated according to RECIST 1.1 criteria and platinum sensitivity, measured as platinum-free interval (PFI), progression free (PFS), and overall survival (OS) was explored. The MAGE-A10 protein expression predicted unresponsiveness to platinum-based chemotherapy (
Identifiants
pubmed: 37835391
pii: cancers15194697
doi: 10.3390/cancers15194697
pmc: PMC10571787
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Histochem. 2014 Jun;116(5):740-6
pubmed: 24560456
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34413169
J Histochem Cytochem. 2018 Feb;66(2):67-83
pubmed: 29164988
Ann Surg Oncol. 2010 Jun;17(6):1642-8
pubmed: 20165986
Int J Cancer. 1999 Jan 18;80(2):219-30
pubmed: 9935203
Clin Oral Investig. 2014 Jan;18(1):189-97
pubmed: 23430338
Int J Mol Sci. 2023 Jun 29;24(13):
pubmed: 37446039
Sci Rep. 2015 Jul 15;5:12104
pubmed: 26175056
Int J Cancer. 1996 Nov 15;68(4):471-8
pubmed: 8945618
Obstet Gynecol. 2015 Jul;126(1):171-4
pubmed: 26241270
Int J Cancer. 2007 Jan 15;120(2):337-43
pubmed: 17066423
Ann Oncol. 2017 Apr 1;28(4):727-732
pubmed: 27993805
Nat Rev Cancer. 2003 Jul;3(7):502-16
pubmed: 12835670
J Neurosurg Pediatr. 2008 Apr;1(4):305-13
pubmed: 18377306
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34233963
Nat Rev Cancer. 2005 Aug;5(8):615-25
pubmed: 16034368
Cancer Res. 2001 Aug 1;61(15):5850-6
pubmed: 11479225
Neuro Oncol. 2011 Feb;13(2):165-75
pubmed: 21177782
Am J Cancer Res. 2022 Feb 15;12(2):681-694
pubmed: 35261795
J Immunother. 2006 Sep-Oct;29(5):499-511
pubmed: 16971806
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
J Transl Med. 2022 Dec 3;20(1):556
pubmed: 36463238
Am J Surg Pathol. 2004 Apr;28(4):496-504
pubmed: 15087669
Semin Cancer Biol. 2012 Jun;22(3):194-207
pubmed: 22406545
Mol Diagn Ther. 2020 Oct;24(5):537-555
pubmed: 32548799
Lancet Oncol. 2003 Feb;4(2):104-9
pubmed: 12573352
Immunogenetics. 1994;40(5):360-9
pubmed: 7927540
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
J Clin Invest. 2013 Apr;123(4):1833-43
pubmed: 23549087
Front Oncol. 2023 May 18;13:1104547
pubmed: 37274261
Cancer Res. 2010 Dec 15;70(24):10362-70
pubmed: 21056992
Am J Transl Res. 2020 Nov 15;12(11):7002-7019
pubmed: 33312347
Cancer Immun. 2007 Aug 24;7:15
pubmed: 17715884
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Clin Cancer Res. 2003 Dec 15;9(17):6453-60
pubmed: 14695148
Pathol Oncol Res. 2015 Apr;21(2):347-56
pubmed: 25108408
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Eur J Cancer. 2003 Jan;39(1):70-7
pubmed: 12504661
Clin Cancer Res. 2011 Jul 1;17(13):4309-19
pubmed: 21565982
Cancers (Basel). 2023 Mar 15;15(6):
pubmed: 36980665
Arch Gynecol Obstet. 2023 Jul;308(1):231-237
pubmed: 36680573
Clin Oral Investig. 2018 Apr;22(3):1477-1486
pubmed: 29034444
PLoS One. 2014 Aug 07;9(8):e104099
pubmed: 25101620
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35086946
Br J Cancer. 2000 Jul;83(2):204-8
pubmed: 10901371
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Gynecol Oncol. 2017 Jun;145(3):420-425
pubmed: 28392127
J Clin Oncol. 2005 Dec 10;23(35):9008-21
pubmed: 16061912
Int J Gynecol Cancer. 2011 May;21(4):771-5
pubmed: 21543939
Nat Med. 2023 Jan;29(1):104-114
pubmed: 36624315
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Clin Cancer Res. 2003 Jul;9(7):2778-85
pubmed: 12855658
Int J Cancer. 2011 Sep 1;129(5):1137-48
pubmed: 21710496
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
J Immunother. 2021 Apr 1;44(3):95-105
pubmed: 33284140
Cancer Res. 2004 Dec 15;64(24):9167-71
pubmed: 15604288